10.19.21 -- Developing And Advancing Multi-Chain Biotherapeutics

In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

To de-risk the production of bispecific molecules, Lonza has developed a toolbox approach that allows for screening of titer and product assembly at an early stage in your product’s life cycle.

Learn how in silico and in vitro protein design and optimization tools can help you to identify and mitigate manufacturing, development, and immunogenicity risks to reduce attrition and to improve the quality and safety of your therapeutic proteins.

Many initially promising biotherapeutic candidates fail due to lack of efficacy or safety, but there are also candidates that fail due to stability, aggregation, and other issues related to cell line or process issues. Prepare for a successful transition to bring your drug candidate from discovery to the clinic.